Biopharma's AI Revolution Stalls on a Hidden Weak Spot: Data Context

CAMBRIDGE, Mass. – April 21, 2026 – The biopharmaceutical industry has staked its future on artificial intelligence, pouring billions into algorithms designed to discover new drugs, streamline clinical trials, and revolutionize manufacturing. Yet, a growing body of evidence suggests these transformative ambitions are hitting a critical, often-overlooked bottleneck: the data itself.

According to a new insight piece from global informatics firm Zifo, the much-hyped power of AI is being neutralized by a fundamental weakness—a lack of scientific context. In the piece, titled 'Biopharma Companies Discover AI's Weak Spot: Scientific Context,' Zifo’s Data Stewardship Practice Lead, Marilyne Labasque, PhD, argues that even the most advanced AI systems are rendered ineffective when fed a diet of fragmented, poorly described, and siloed scientific data. This isn't a failure of the algorithm, but a failure of the foundation.

The problem is pervasive. Industry reports corroborate this view, with a recent Veeva survey finding that a staggering 89% of biopharma companies have failed to scale most of their AI initiatives due to data challenges. Gartner has predicted that through 2026, 60% of all AI projects will be abandoned, not because the models are flawed, but because the data is not ready. In a sector where a single mistake can cost years of research and billions of dollars, the old adage of "garbage in, garbage out" has taken on a more dangerous form: "garbage in, gospel out," where flawed AI outputs are mistakenly trusted, leading research teams down costly dead ends.

The High Cost of Ambiguity

The challenge stems from the complex and fragmented nature of scientific data. Information from multimodal assays, electronic lab notebooks (ELNs), manufacturing control systems (CMC), and clinical trials often exists in isolated systems with inconsistent naming conventions and missing metadata. Without a disciplined approach, the meaning of a data point can depend entirely on an individual scientist's memory—a fragile and unscalable system.

This lack of coherence has a tangible cost. It manifests as repeated experiments, stalled digital transformation programs, and hours spent by highly skilled scientists on manual data wrangling instead of innovation. Industry analysis reveals that nearly all biopharma leaders—96% in one survey—report their data is not structured or ready for AI, and two-thirds have abandoned projects entirely because of bad data.

As AI models increase the scale and speed of data analysis, the cost of ambiguity rises exponentially. Decisions that were once recoverable through manual review become opaque and potentially dangerous when automated systems operate on poorly described information. This not only hampers innovation but also introduces significant risk, undermining traceability, reproducibility, and regulatory compliance.

Data Stewardship: The Unsung Hero of AI

To bridge this gap, Zifo and other industry experts advocate for a renewed focus on data stewardship—the operational discipline of managing and overseeing an organization's data assets. Far from being a mundane administrative task, stewardship is being reframed as the critical enabler that turns raw data into a trustworthy, AI-ready strategic asset.

Effective stewardship goes beyond simple data cleaning. It involves a layered approach that builds a foundation for trustworthy AI. This begins with trusted data—ensuring every data point is accurate, attributable, and traceable to its origin. The next layer involves FAIR-driven enhancements, which enrich the data with standardized terminologies and interoperable formats so it is Findable, Accessible, Interoperable, and Reusable for both humans and machines. A common misconception is that data quality and FAIR principles are the same; they are not. A dataset can be perfectly accurate (high quality) but useless to an AI system if it's not described in a machine-actionable way (low FAIR score). Stewardship is the discipline that unifies both.

Finally, a human layer of data stewards and owners provides long-term accountability, monitoring data quality, guiding its lifecycle, and safeguarding its ethical use. This systematic approach shortens the time scientists spend searching for information, slows data decay, and lays a foundation for AI that can be trusted and explained.

From Theory to Practice and Compliance

The impact of robust stewardship is not merely theoretical. The Zifo report highlights a practical example where a large pharmaceutical organization struggled with thousands of inconsistent equipment records across its Chemistry, Manufacturing, and Controls (CMC) division. By standardizing and harmonizing these records, the company established a unified data model that allowed scientists to find critical information in hours instead of days, reduce integration errors, and close significant traceability gaps.

This focus on traceability and integrity is increasingly critical from a regulatory standpoint. Agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are sharpening their focus on data integrity, demanding that data adhere to ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, and more). As AI-driven submissions become more common, companies will be required to demonstrate a clear and auditable lineage for the data used to train and validate their models.

Effective data stewardship directly supports these regulatory demands by embedding clarity and traceability into daily scientific practice. It ensures that when an AI model produces a novel insight or recommendation, the organization can confidently explain and defend the underlying data, satisfying both scientific rigor and regulatory scrutiny.

Ultimately, the journey to becoming an AI-driven biopharma organization does not start with hiring more data scientists or buying the latest algorithm. It begins with the leadership mandate to treat data as a core strategic asset. This requires establishing repeatable assessment practices, training stewards, and making the value of data governance visible through shared metrics like reduced rework and faster analytics cycles. For organizations aiming for scientific excellence in the age of AI, robust data stewardship is no longer optional; it is the operational backbone of future innovation.